Clinical Trials

Lymphoma, Mantle-Cell

NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Phase 1/2 Completed

97 enrolled 43 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06742996 2026-02-20

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Phase 3 Recruiting

300 enrolled

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT06854003 2026-02-20

BRAZAN

60 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT07341191 2026-02-12

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

40 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT06558604 2026-02-11

GLOASIS

100 enrolled

Lymphoma, Mantle-Cell

NCT04116437 2026-01-28

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Phase 2 Completed

96 enrolled

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07261163 2025-12-03

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

37 enrolled

Lymphoma, Mantle-Cell

NCT04172246 2025-11-21

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

Phase 1/2 Completed

55 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06839053 2025-11-19

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT06029309 2025-10-06

ZANU-TAFA

Phase 1/2 Recruiting

27 enrolled

Phase 3 Active not recruiting

Lymphoma, Mantle-Cell

NCT04002297 2025-09-26

MANGROVE

510 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT06859008 2025-08-05

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

37 enrolled

Phase 3 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04662255 2025-05-28

BRUIN-MCL-321

500 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05635162 2025-04-16

ZEBRA

50 enrolled

86 enrolled 16 charts 1 FDA

Lymphoma, Mantle-Cell

NCT03206970 2024-10-26

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Phase 2 Completed

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT04624958 2024-10-18

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

42 enrolled

Lymphoma, Mantle-Cell

NCT06341556 2024-09-04

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

52 enrolled

Lymphoma, Mantle-Cell

NCT06504199 2024-08-09

ZGR

39 enrolled

Lymphoma, Mantle-Cell

NCT06427213 2024-05-23

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

41 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT06255704 2024-02-13

Z+RCHOP/RDHAP

23 enrolled

Lymphoma, Mantle-Cell

NCT06136351 2023-11-29

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

23 enrolled

Lymphoma, Mantle-Cell

NCT02914938 2023-05-09

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Phase 1 Terminated

97 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05504603 2022-08-17

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

Phase 2 Unknown

20 enrolled